Latest Hotspot

Evaxion secures initial pre-clinical validation for its mRNA Gonorrhea vaccine candidate, EVX-B2

11 September 2024
3 min read

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a technology-driven biotechnology firm in the clinical stage that focuses on creating AI-Immunology based vaccines, has released new pre-clinical results. These findings showcase the efficacy of its innovative EVX-B2 mRNA Gonorrhea vaccine candidate in eradicating gonorrhea bacteria through the induction of a specialized immune response.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 应用程序

描述已自动生成

Today at the 18th Vaccine Congress in Lisbon, Portugal, new data will be unveiled demonstrating strong Proof-of-Concept (PoC) for the mRNA-based iteration of EVX-B2 in a pre-clinical environment.

Originally, EVX-B2 was engineered as a protein-based vaccine candidate, which had already achieved pre-clinical PoC. The latest pre-clinical findings for the mRNA-based version of the vaccine confirm that AI-Immunology™ identified antigens are versatile across different vaccine technologies. The data were generated in partnership with Afrigen Biologics.

“We are excited to announce the pre-clinical PoC for the mRNA version of EVX-B2, which marks another milestone for our 2024 objectives. It is gratifying to witness further validation of our AI-Immunology™ platform and its potential in developing innovative treatments, including for bacterial diseases. Currently, there is no existing vaccine for Gonorrhea, so this could lead to a pioneering solution. Additionally, this data reaffirms that our platform is versatile in terms of delivery modalities, presenting a compelling value proposition for both current and prospective partners,” stated Christian Kanstrup, CEO of Evaxion.

Petro Terblanche, CEO of Afrigen Biologics, also expressed enthusiasm about the outcomes of the collaboration: “With rising global challenges in antimicrobial resistance and the public health priority of effective interventions against increases in Gonorrhea cases, we are thrilled to have reached pre-clinical PoC for EVX-B2’s mRNA version, which shows promise as a future vaccine product.”

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of September 11, 2024, there are 75 investigational drugs for the Gonorrhe, including 24 targets, 70 R&D institutions involved, with related clinical trials reaching 422, and as many as 7785 patents.

EVX-B2 is a prophylactic vaccine being developed by Evaxion Biotech A/S for the prevention of gonorrhea, which falls under the therapeutic areas of Infectious Diseases and Urogenital Diseases. The drug is currently in the preclinical phase, meaning it is undergoing laboratory and animal testing to determine its safety and efficacy before advancing to clinical trials in humans.

图形用户界面, 文本, 应用程序

描述已自动生成

Allist’s Furmonertinib Monotherapy Study Showcases Promising Results in First-Line Treatment of EGFR PACC Mutant NSCLC
Hot Spotlight
7 min read
Allist’s Furmonertinib Monotherapy Study Showcases Promising Results in First-Line Treatment of EGFR PACC Mutant NSCLC
11 September 2024
ArriVent BioPharma and Allist Pharmaceuticals unveiled groundbreaking data from their global Phase Ib proof-of-concept randomized study (FURTHER) at the IASCLC 2024 WCLC.
Read →
Successful Phase 1 Results for TERN-601, a Daily Oral GLP-1R Agonist in Obesity Treatment
Latest Hotspot
3 min read
Successful Phase 1 Results for TERN-601, a Daily Oral GLP-1R Agonist in Obesity Treatment
11 September 2024
Terns Pharmaceuticals Reports Successful Phase 1 Results for TERN-601 Daily Oral GLP-1R Agonist in Obesity Treatment.
Read →
Preview of Clinical Results from ESMO 2024!
Feature Updates
3 min read
Preview of Clinical Results from ESMO 2024!
11 September 2024
The Synapse database immediately launched a search portal for ESMO clinical results data, facilitating user access.
Read →
IDeate-Lung01 Phase 2 Trial: Promising Response Rates with Ifinatamab Deruxtecan in Advanced Small Cell Lung Cancer
Latest Hotspot
3 min read
IDeate-Lung01 Phase 2 Trial: Promising Response Rates with Ifinatamab Deruxtecan in Advanced Small Cell Lung Cancer
11 September 2024
The IDeate-Lung01 Phase 2 Trial shows Ifinatamab Deruxtecan maintains encouraging objective response rates in patients with advanced-stage small cell lung cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.